Video software platform Vimeo (NASDAQ:VMEO) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $104.7 million. Its GAAP profit of $0.04 per share was significantly above analysts’ consensus estimates.
SI-BONE INC reports mixed Q2 2025 results with revenue slightly below estimates but beats on EPS, driving a positive market reaction. Strong growth and raised guidance signal confidence.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Telehealth company Hims & Hers Health (NYSE:HIMS) fell short of the market’s revenue expectations in Q2 CY2025, but sales rose 72.6% year on year to $544.8 million. On the other hand, the company expects next quarter’s revenue to be around $580 million, close to analysts’ estimates. Its GAAP profit of $0.17 per share was 13% above analysts’ consensus estimates.
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 21.8% year on year to $349.4 million. Its non-GAAP profit of $1.49 per share was 1.8% above analysts’ consensus estimates.
Marketing analytics software Semrush (NYSE:SEMR) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 19.7% year on year to $108.9 million. On the other hand, next quarter’s revenue guidance of $111.6 million was less impressive, coming in 2.9% below analysts’ estimates. Its GAAP loss of $0.04 per share was significantly below analysts’ consensus estimates.
ZoomInfo Q2 2025 earnings beat estimates with $306.7M revenue and $0.25 EPS, sparking a 6.95% stock surge. New CFO appointment and strong demand for its intelligence platform drive optimism.
Wellness company Medifast (NYSE:MED) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, but sales fell by 37.4% year on year to $105.6 million. On the other hand, next quarter’s revenue guidance of $80 million was less impressive, coming in 14.7% below analysts’ estimates. Its GAAP profit of $0.22 per share was significantly above analysts’ consensus estimates.
ODDITY Tech (NASDAQ: ODD) beat Q2 2025 revenue and EPS estimates but saw a 13% stock drop post-earnings. Strong profitability contrasts with investor concerns over future growth. Full-year outlook raised, yet market reaction remains cautious.
Energy and renewable energy projects company Ameresco (NYSE:AMRC) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 7.8% year on year to $472.3 million. The company’s full-year revenue guidance of $1.9 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $0.27 per share was significantly above analysts’ consensus estimates.
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.9% year on year to $825.4 million. The company’s full-year revenue guidance of $3.16 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $1.44 per share was 42.3% above analysts’ consensus estimates.
Syndax Pharmaceuticals reported mixed Q2 2025 results, beating revenue estimates with $37.96M but posting an EPS loss of ($0.83). Revuforj sales surged 43%, while shares dipped 3.66% post-earnings.
Infrastructure consulting service company AECOM (NYSE:ACM) fell short of the market’s revenue expectations in Q2 CY2025, with sales flat year on year at $4.18 billion. Its non-GAAP profit of $1.34 per share was 6.2% above analysts’ consensus estimates.
Simon Property Group (SPG) beat Q2 2025 earnings estimates, raised guidance, and increased its dividend, signaling strong financial health and investor confidence.
Restaurant software company (NYSE:OLO) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 21.6% year on year to $85.72 million. Its non-GAAP profit of $0.07 per share was in line with analysts’ consensus estimates.
